Investor Relations

Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies for the treatment of cancer and immune-inflammatory related diseases. Our portfolio of commercial products include REVLIMID®, VIDAZA®, THALOMID®, POMALYST®/IMNOVID®, ABRAXANE®, and ISTODAX®. The drug candidates in our pipeline are at various stages of preclinical and clinical development. These candidates include our IMiDs® compounds, which are a proprietary class of compounds that have certain immunomodulatory and other biologically important properties in addition to our leading oral anti-inflammatory agents and cellular therapies. We believe our commercial stage products and the depth of our product pipeline, provide the catalysts for future growth.


  • Current Quote
  • Stock Charts
NASDAQ: CELG
108.20
+ 0.85 (0.79%)
Day High: 109.21
Day Low: 107.89
Volume: 3,862,900
4:00 PM ET on Nov 21, 2014
Delayed at least 20 minutes.